Takeda Pharmaceutical Co Ltd
TAK15.025USD
-0.084-0.56%
收盤 04/25, 16:00（美東）報價延遲15分鐘
23.82B總市值
0.11本益比TTM
關於 Takeda Pharmaceutical Co Ltd 公司
武田藥品株式會社是一家日本公司，主要從事藥品的研發、製造、銷售和許可。公司專注於胃腸道疾病、罕見疾病、血漿衍生物（免疫疾病）、腫瘤學（癌症）和神經科學（神經精神疾病）的主要業務領域。公司專注於三個研發領域：創新生物製藥，重點關注胃腸道和炎症疾病、神經科學和腫瘤學，以及血漿衍生物和疫苗。大多數藥品用於治療重點疾病領域和血漿衍生物領域的罕見疾病。公司在日本、美國、歐洲和中國開展業務。
公司簡介
公司代碼TAK
公司名稱Takeda Pharmaceutical Co Ltd
上市日期May 16, 1949
成立日期1925
CEOMr. Christophe Weber
員工數量49281
證券類型Depository Receipt
年結日May 16
公司地址4F
城市CHUO-KU
上市交易所NYSE Consolidated
國家Japan
郵編103-8668
電話81332782111
網址https://www.takeda.com/
公司代碼TAK
上市日期May 16, 1949
成立日期1925
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
收入明細
單位: JPY更新時間: 4月6日 週日
單位: JPY更新時間: 4月6日 週日
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
業務JPY
名稱
營收
佔比
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
地區JPY
名稱
營收
佔比
United States
593.84B
51.90%
Europe And Canada (Country)
262.60B
22.95%
Japan
108.34B
9.47%
Asia
69.19B
6.05%
Latin America
58.66B
5.13%
Other
51.53B
4.50%
業務
地區
業務JPY
名稱
營收
佔比
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
股東統計
更新時間: 4月8日 週二
更新時間: 4月8日 週二
持股股東
股東類型
持股股東
股東統計
佔比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
持股股東
股東統計
佔比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
股東類型
股東統計
佔比
Investment Advisor
1.55%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.27%
Research Firm
0.14%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Other
97.64%
機構持股
更新時間: 1月19日 週日
更新時間: 1月19日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
574
73.02M
2.32%
-10.12M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
2022Q4
637
69.93M
2.25%
-40.01M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Capital Research Global Investors
13.16M
0.42%
+25.31K
+0.19%
Dec 31, 2024
Parametric Portfolio Associates LLC
5.14M
0.16%
+961.51K
+23.02%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.22M
0.13%
-419.02K
-9.04%
Dec 31, 2024
Fidelity Management & Research Company LLC
3.33M
0.11%
+438.69K
+15.18%
Dec 31, 2024
First Trust Advisors L.P.
3.24M
0.1%
+62.72K
+1.97%
Dec 31, 2024
Renaissance Technologies LLC
3.08M
0.1%
-139.40K
-4.33%
Dec 31, 2024
Brandes Investment Partners, L.P.
3.04M
0.1%
-192.02K
-5.94%
Dec 31, 2024
Goldman Sachs Asset Management, L.P.
2.32M
0.07%
+131.24K
+6.01%
Dec 31, 2024
Van Eck Associates Corporation
2.21M
0.07%
+35.19K
+1.62%
Dec 31, 2024
Aperio Group, LLC
2.20M
0.07%
+313.03K
+16.56%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
VanEck Pharmaceutical ETF
4.7%
SGI Enhanced Global Income ETF
3.05%
Roundhill GLP-1 & Weight Loss ETF
2.1%
ActivePassive International Equity ETF
0.6%
First Trust Value Line Dividend Index Fund
0.45%
Pacer Trendpilot International ETF
0.26%
Avantis International Equity ETF
0.07%
Avantis Responsible International Equity ETF
0.07%
DFA Dimensional International Core Equity 2 ETF
0%
Pacer Developed Markets International Cash Cws 100
0%
查看更多
VanEck Pharmaceutical ETF
佔比4.7%
SGI Enhanced Global Income ETF
佔比3.05%
Roundhill GLP-1 & Weight Loss ETF
佔比2.1%
ActivePassive International Equity ETF
佔比0.6%
First Trust Value Line Dividend Index Fund
佔比0.45%
Pacer Trendpilot International ETF
佔比0.26%
Avantis International Equity ETF
佔比0.07%
Avantis Responsible International Equity ETF
佔比0.07%
DFA Dimensional International Core Equity 2 ETF
佔比0%
Pacer Developed Markets International Cash Cws 100
佔比0%
分紅派息
近5年累計派現
1.42T
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據